Literature DB >> 7399718

The role of schedule of antibiotic therapy on the neutropenic patient.

G P Bodey, M Valdivieso, B S Yap.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7399718     DOI： 10.1007/bf01644940

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  8 in total

1.  Multiple-dose pharmacokinetics of ceftazidime in cancer patients.

Authors:  I Garcia; V Fainstein; R G Smith; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

2.  Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; P Fontijne; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

Review 3.  Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

Authors:  M LeBel; M Spino
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

4.  Influence of four modes of administration on penetration of aztreonam, cefuroxime, and ampicillin into interstitial fluid and fibrin clots and on in vivo efficacy against Haemophilus influenzae.

Authors:  G Y Lavoie; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

5.  Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

6.  Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever.

Authors:  G Bodey; A Reuben; L Elting; H Kantarjian; M Keating; F Hagemeister; C Koller; W Velasquez; N Papadopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

7.  Clinical pharmacology of ceftriaxone in patients with neoplastic disease.

Authors:  P Salvador; R G Smith; R E Weinfeld; D H Ellis; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Clinical pharmacology of moxalactam in patients with malignant disease.

Authors:  E H Estey; S S Weaver; D H Ho; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.